Evidence Table 112. KQ3—Dichotomous outcomes—Abnormal ECG

| **Author Year**  **Study Design** | **Definition of outcome (if relevant)** | **CHD Risk Category** | **CVD drug**  **(dose mg/d))** | **Group 1: Name (supplement)** | **N1** | **N1 with event** | **Group 2: Name** | **N2** | **N2 with event** | **Estimates of Group Differences** | **Additional comments** | **Overall Risk of Bias (ROB) Assessment** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Reyes 198459  Parallel | N/A | Mixed:  Low and/or Moderate | Hydrochlorothiazide  (50) | Magnesium | 13 | NR | Placebo | 8 | NR | NR | Results state only that 'no statistically significant changes affected the electrocardiogram or the plasma variables studied during the trial'. Methods do not state which electrocardiographic measurements were taken. | Medium |
| Playford 200358  Parallel | N/A | At high risk for CHD | Fenofibrate  (200) | Co-Q10 | 18 | NR | No Treatment | 17 | NR | NR |  | Low-medium |
| Di Spirito 200819  Crossover | N/A | At low risk for CHD (0-1 risk factors) | Atorvastatin (80) | Omega-3 | 50 |  | No Treatment | 50 |  | NR | No treatment related trends regarding ECG or other clinical or laboratory markers were found (no specific data) | Medium |
| McKenney 200645  Crossover | N/A | Mixed:  Low and/or Moderate | Simvastatin (80) | Omega-3 | 24 |  | No Treatment | 24 |  | NR |  | Medium |
| Kim 201035  Crossover | N/A | Mixed:  Low and/or Moderate | Ticlopidine (250 –single dose) | Gonkgo Biloba | 24 | 0 | No Treatment | 24 | 0 | NR |  | Medium |